Filter Results

Clinical Studies

Open

  • Thoracic Specimen Registry Rochester, Minn., Scottsdale/Phoenix, Ariz.

    The primary objective of this proposal is to develop a Thoracic Specimen Registry at Mayo Clinic. The purpose of the registry will be to support ongoing research in the etiology, early diagnosis, clinical management, and prognosis of lung cancer and other cancers and diseases of the thorax by developing a complete repository of specimens from patients with thoracic disease including but not limited to suspected lung cancer, mediastinal and pleural tumors and from patients at a very high risk of developing other thoracic cancers or other thoracic diseases. 

Contact Us for the Latest Status

  • Genetic Determinants of Lung Cancer Survival Rochester, Minn.

    The purpose of this study is to collect medical and personal histories, blood and/or tumor tissue samples from patients who are long-term survivors of lung cancer. This study will help us to develop better ways to provide care and advice, develop better treatments to minimize long-term side effects, and improve the quality of life and outcome of lung cancer patients. This study will also help us to learn whether certain genes (inherited factors from your parents) increase the risk of developing or dying of lung cancer.

Closed for Enrollment

  • Alpha-1 AD Carriers and Lung Cancer Risk Rochester, Minn.

    The purpose of this study is to collect medical and family histories, blood and/or tumor tissue samples from patients who are being tested for or who have or had lung cancer. This study will help us to develop better ways to screen people at risk for lung cancer and develop better treatments for patients diagnosed with lung cancer. This study will also help us to learn whether certain genes (inherited factors from your parents) increase the risk of developing lung cancer.

     

  • Return of Actionable Variants Empirical (Rave) Study: eMERGE III in Arizona Scottsdale/Phoenix, Ariz.

    The purpose of this study is to form processes to get findings from targeted gene sequencing that can be acted on using two common actionable genetic disorders–familial hyperlipidemia and familial colorectal cancer. 

.